1 Top Growth Stock to Buy and Hold for 10 Years
A lot will change in the next 10 years, but our need for innovative medicines is unlikely to be one of them. That's one thing that makes some biotech companies exciting long-term investment opportunities, at least highly innovative ones that look well-positioned to deliver solid clinical and regulatory progress over long periods.
Let's consider one company that might have what it takes: Sarepta Therapeutics (NASDAQ: SRPT). The biotech has performed well so far this year, and it could maintain that momentum for a while. Let's find out why.
Sarepta Therapeutics' strong performance on the stock market this year reflects the fact that investors expect it to earn a crucial approval from the U.S. Food and Drug Administration (FDA). But first, some background information.
Source Fool.com
Sarepta Therapeutics Aktie
Die Community ist bei Sarepta Therapeutics noch unentschieden: Nur wenige Einschätzungen.
Ein Kursziel von 130 € für Sarepta Therapeutics zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 128.25 €.
